Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma — Richard S. Finn (2025) | RDL Network
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma
R.S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, S. Qin, M. Ikeda, R. Xu, Julien Edeline, B-Y. Ryoo, Z. Ren, Ann‐Lii Cheng, P.R. Galle, S. Kaneko, H. Kumada, A. Wang, K. Mody, L. Dubrovsky, A.B. Siegel, J. Llovet
Richard S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Hiromitsu Kumada, Simcha Pollack, Kalgi Mody, Leonid Dubrovsky, David E. Adelberg, Josep M. Llovet
Richard S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Hiromitsu Kumada, Anran Wang, Kalgi Mody, Leonid Dubrovsky, Abby B. Siegel, Josep M. Llovet
Josep M. Llovet, Masatoshi Kudo, Ann‐Lii Cheng, Richard S. Finn, Peter R. Galle, Shuichi Kaneko, Tim Meyer, Shukui Qin, Corina E. Dutcus, Erluo Chen, Leonid Dubrovsky, Andrew X. Zhu
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus,
Discussion(0)
No comments yet. Be the first to comment.